More than three quarters of patients with chronic limb-threatening ischemia (CLTI) and no revascularization options were able to avoid above-the-ankle amputation through a new technique called ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved a transcatheter deep venous arterialization system for treatment of chronic limb-threatening ...

MARLBOROUGH, Mass.- Boston Scientific announced today that the U.S Food and Drug Administration (FDA) has approved the VICI VENOUS STENT™ System for the treatment of iliofemoral venous obstructive ...

Boston Scientific announced that a stent system for the treatment of patients with iliofemoral venous obstructive disease has been approved by the FDA. The venous stent system (Vici) is strong and ...

Approximately 20% of patients with chronic limb-threatening ischemia have no revascularization options, leading to above-ankle amputation. Transcatheter arterialization of the deep veins is a ...

Early recognition of chronic venous insufficiency helps improve outcome and reduces the need for surgical intervention. Chronic venous insufficiency (CVI) affects 10% to 35% of adults in the United ...

A thermal-imaging tool to screen for chronic wounds could enable nurses to identify these hard-to-heal sores during the first assessment at a person's home. Nearly half a million Australians live with ...

Brooklyn Park, MN - The Food and Drug Administration (FDA) has approved central venous access for a fluid-removal system, CHF Solutions announced. The company's System 100 is a mechanical pump and ...

(RTTNews) - Medical devices maker Boston Scientific Corp. (BSX) announced Monday that the U.S Food and Drug Administration (FDA) has approved the VICI VENOUS STENT System for the treatment of ...